Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.

Saved in:
Bibliographic Details
Title: Author Correction: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials.
Authors: Kaul I; Bristol Myers Squibb, Princeton, NJ, USA., Sawchak S; Bristol Myers Squibb, Princeton, NJ, USA., Claxton A; Bristol Myers Squibb, Princeton, NJ, USA., Sauder C; Bristol Myers Squibb, Princeton, NJ, USA., Hassman HH; CenExel-Hassman Research Institute, Marlton, NJ, USA., Kakar R; Segal Trials, Lauderhill, FL, USA., Walling DP; CenExel-Collaborative Neuroscience Research, Los Alamitos, CA, USA., Citrome L; New York Medical College, Valhalla, NY, USA., Zhu H; Bristol Myers Squibb, Princeton, NJ, USA., Miller AC; Bristol Myers Squibb, Princeton, NJ, USA., Brannan SK; Bristol Myers Squibb, Princeton, NJ, USA. sbrannan@karunatx.com.
Source: Schizophrenia (Heidelberg, Germany) [Schizophrenia (Heidelb)] 2025 Mar 18; Vol. 11 (1), pp. 44. Date of Electronic Publication: 2025 Mar 18.
Publication Type: Published Erratum
Journal Info: Publisher: Springer Nature Limited Country of Publication: Germany NLM ID: 9918367987006676 Publication Model: Electronic Cited Medium: Internet ISSN: 2754-6993 (Electronic) Linking ISSN: 27546993 NLM ISO Abbreviation: Schizophrenia (Heidelb) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2754-6993
DOI:10.1038/s41537-025-00595-0